John Overdeck’s GT Biopharma GTBP Stock Holding History

John Overdeck’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,003	Closed	-$549K	–	3343
2021 Q4	$549K	Buy	6,003 +576	+11%	+$86.2K	﹤0.01%	3160
2021 Q3	$1.1M	Buy	+5,427	New	+$1.63M	﹤0.01%	2536

Other funds holding GTBP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

John Overdeck's GTBP Position: Q1 2022 in Review

John Overdeck sold out of GT Biopharma (GTBP) in Q1 2022, closing a stake of 6,003 shares — an estimated $549K sold.

John Overdeck first reported a position in GTBP in Q3 2021 and held it in 2 quarters. The position peaked at $1.1M in Q3 2021. 57 funds tracked by Wall St. Rank hold GTBP as of Q1 2022.

John Overdeck reported no remaining GT Biopharma position as of Q1 2022 after selling out during the quarter.
John Overdeck sold 6,003 GT Biopharma shares in Q1 2022, an estimated $549K.
John Overdeck first reported a position in GT Biopharma in Q3 2021 and held it in 2 quarters.
John Overdeck's GT Biopharma position peaked at $1.1M in Q3 2021.
57 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2022.

Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.